You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The latest news on next-generation sequencing.
For the three months ended April 30, the firm's revenues were $1.24 billion, flat with $1.24 billion in Q2 2019 but beating Wall Street analysts' average estimate of $1.21 billion.
The companies collaborated in Wuhan during the COVID-19 outbreak, using Darui's pathogenic microorganism detection kits on Genetron's next-generation sequencer.
French startup SeqOne has adapted its sequencing data-analysis platform to support a new method for high-throughput processing of coronavirus tests in its home country.
Children's Hospital Los Angeles used a SARS-CoV-2 sequencing panel to determine if patients had become infected from the same source as healthcare workers.
Several groups are developing diagnostic viral genome sequencing assays and panels, which promise high sensitivity and additional information on viral origin and spread.
The firms are developing a kit-based CDx to detect NTRK gene fusions, including NTRK1, NTRK2 and NTRK3, for Bayer's Vitrakvi cancer treatment.
The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.
The May 8 settlement resolves all claims and counterclaims relating to noninvasive prenatal testing and pre-implantation genetic screening and diagnosis.
The firm withdrew its 2020 revenue guidance and missed Wall Street estimates for both revenues and earnings.
Assays like SwabSeq, Dx-Seq, and LAMP-Seq promise to analyze tens to hundreds of thousands of samples in parallel but might be constrained by sample availability.